Увійти

Готові списки джерел за темами / Treatment responder / Статті в журналах

Щоб переглянути інші типи публікацій з цієї теми, перейдіть за посиланням: Treatment responder.

Статті в журналах з теми "Treatment responder"

Автор: Grafiati

Опубліковано: 3 червня 2025

Оновлено: 31 липня 2025

Оформте джерело за APA, MLA, Chicago, Harvard та іншими стилями

Оберіть тип джерела:

Ознайомтеся з топ-50 статей у журналах для дослідження на тему "Treatment responder".

Біля кожної праці в переліку літератури доступна кнопка «Додати до бібліографії». Скористайтеся нею – і ми автоматично оформимо бібліографічне посилання на обрану працю в потрібному вам стилі цитування: APA, MLA, «Гарвард», «Чикаго», «Ванкувер» тощо.

Також ви можете завантажити повний текст наукової публікації у форматі «.pdf» та прочитати онлайн анотацію до роботи, якщо відповідні параметри наявні в метаданих.

Переглядайте статті в журналах для різних дисциплін та оформлюйте правильно вашу бібліографію.

1

Lee, Seo-Ho, Dennis M. Bonal, Diana Olguta Treaba, et al. "Sry-Box Transcription Factor 9 (SOX9)-Driven Mesenchymal Stromal Cell Differentiation Signature As a Determinant of Induction Chemotherapy Responsiveness in Acute Myeloid Leukemia Core Bone Marrow Biopsies." Blood 142, Supplement 1 (2023): 4299. http://dx.doi.org/10.1182/blood-2023-189679.

Повний текст джерела

Анотація:

Leukemic clones in acute myeloid leukemia (AML) alter the bone marrow (BM) microenvironment so that the normal functions of hematopoietic stem cells (HSCs) are interrupted, aiding malignant progression. Accumulating evidence points to a protective role that the microenvironment provides for the AML clone (Colmone et al., Science, 2008). It is therefore crucial to detail the mechanisms by which the BM stroma promotes leukemia progression to inform the development of more effective targeted therapies. Most studies focused on detailing the role of BM stroma in AML etiology use BM aspirates, which

Стилі APA, Harvard, Vancouver, ISO та ін.

2

Barrow, Rhiannon, James A. Poulter, Martina A. Finetti, Erica Wilson, Colin A. Johnson, and Lucy Stead. "Modulation of GABA Neurotransmitter Signalling Impacts Glioblastoma Spheroid Growth and Response to Standard Treatment." Neuro-Oncology 24, Supplement_4 (2022): iv3—iv4. http://dx.doi.org/10.1093/neuonc/noac200.013.

Повний текст джерела

Анотація:

Abstract AIMS We have identified two subtypes within glioblastoma (GBM), defined by whether a specific subset of genes is upregulated (Up responders) or downregulated (Down responders) in response the standard treatment. The biology of therapy-driven transcriptional reprogramming in the two subtypes suggests the differential involvement of GABA neurotransmitter signalling in the underlying treatment resistance mechanisms. Our aim was to address our hypothesis that modulating GABA signalling will impact treatment response in GBM, in different ways for different responder subtypes. METHOD We ide

Стилі APA, Harvard, Vancouver, ISO та ін.

3

Vancappel, Alexis, Yecodji Dansou, Ophelia Godin, et al. "Evolution of Cognitive Impairments in Treatment-Resistant Depression: Results from the Longitudinal French Centers of Expertise for Treatment-Resistant Depression (FACE-DR) Cohort." Brain Sciences 13, no. 7 (2023): 1120. http://dx.doi.org/10.3390/brainsci13071120.

Повний текст джерела

Анотація:

Previous studies set out profound cognitive impairments in subjects with treatment-resistant depression (TRD). However, little is known about the course of such alterations depending on levels of improvement in those patients followed longitudinally. The main objective of this study was to describe the course of cognitive impairments in responder versus non-responder TRD patients at one-year follow-up. The second aim was to evaluate the predictive aspect of cognitive impairments to treatment resistance in patients suffering from TRD. We included 131 patients from a longitudinal cohort (FACE-DR

Стилі APA, Harvard, Vancouver, ISO та ін.

4

Treaba, Diana O., Dennis M. Bonal, Anna D. Chorzalska, et al. "Levels of Osteopontin (SPP1), Osteonectin (SPARC) and Biglycan (BGN) in Acute Myeloid Leukemia Bone Marrow Biopsies Post-Induction Therapy Define the Status of Osteogenic Niche and Show Inverse Correlation with Therapeutic Response." Blood 136, Supplement 1 (2020): 29–30. http://dx.doi.org/10.1182/blood-2020-142604.

Повний текст джерела

Анотація:

Background: Acute Myeloid Leukemia (AML) has a five-year survival rate of 25% and its high mortality is linked to poor response to treatment and relapse. Our understanding of the molecular mechanisms controlling relapse and AML progression is limited. Animal models indicate that AML cells significantly modulate their bone marrow microenvironment inducing gradual loss of endosteal and vascular niches, both playing critical roles in support and maintenance of normal hematopoiesis. The goal of this study was to determine microenvironmental factors driving the gradual retraction of endosteal and v

Стилі APA, Harvard, Vancouver, ISO та ін.

5

Schreiber, S. W., D. B. Clemow, A. Keohane, et al. "P1071 Trajectories of response in patients with moderately-to-severely active ulcerative colitis treated with mirikizumab: Results from the LUCENT-1 study." Journal of Crohn's and Colitis 19, Supplement_1 (2025): i1978—i1979. https://doi.org/10.1093/ecco-jcc/jjae190.1245.

Повний текст джерела

Анотація:

Abstract Background Mirikizumab, an anti-IL-23p19 antibody, demonstrated robust efficacy in improving clinical and endoscopic endpoints with an acceptable safety profile1. We explored the trajectory of response to mirikizumab treatment in patients with moderate-to-severely active ulcerative colitis. Methods Mirikizumab patients described previously1 were assessed via Growth Mixture Model (GMM) to identify distinct clusters based on individual patient response trajectories. The sum of stool frequency and rectal bleeding modified Mayo subscores was used in the GMM to identify trajectories. Week

Стилі APA, Harvard, Vancouver, ISO та ін.

6

Editorial Staff. "Genetic Polymorphisms in GABRD and Treatment Response and Dose in Methadone Maintenance Treatment." Precision Medicine Communications 1, no. 1 (2021): 05–07. http://dx.doi.org/10.55627/pmc.001.01.0073.

Повний текст джерела

Анотація:

Xie and colleagues studied the association between the genetic polymorphs of the GABA receptor delta subunit (GABARD) and dose-response to methadone in heroin addicts subjected to methadone maintenance therapy (MMT) was studied. They investigated two groups: responders and non-responders were created from a total of 286 recruited MMT patients where the parameter for classification was retention time in therapy. According to stabilized methadone dose, 177 patients were divided into subgroups of high dose and low dose. TaqMan SNP assay was used for GABRD genotyping and the following single nucle

Стилі APA, Harvard, Vancouver, ISO та ін.

7

Sudo, Kazuki, Ken Kato, Juntaro Matsuzaki, et al. "Serum microRNAs to predict the response to nivolumab in patients with esophageal squamous cell carcinoma." Journal of Clinical Oncology 35, no. 15_suppl (2017): e14511-e14511. http://dx.doi.org/10.1200/jco.2017.35.15_suppl.e14511.

Повний текст джерела

Анотація:

e14511 Background: A phase II study demonstrated that nivolumab (Nivo), a PD-1 inhibitor, had a meaningful activity for patients with esophageal squamous cell carcinoma. Although several biomarkers, including PD-L1 expression levels in tumor tissue, are explored to predict the efficacy of Nivo, further investigation is needed. Here we evaluated whether serum levels of microRNA (miRNA) could be a candidate of predictive markers. Methods: Among 65 patients who participated in the phase II study (JapicCTINo.142422) and received Nivo 3 mg/kg IV Q2W, 19 patients were treated at our institution. Pat

Стилі APA, Harvard, Vancouver, ISO та ін.

8

Sánchez-Sanz, Alicia, Rafael Muñoz-Viana, Julia Sabín-Muñoz, et al. "Response to Fingolimod in Multiple Sclerosis Patients Is Associated with a Differential Transcriptomic Regulation." International Journal of Molecular Sciences 25, no. 3 (2024): 1372. http://dx.doi.org/10.3390/ijms25031372.

Повний текст джерела

Анотація:

Fingolimod is an immunomodulatory sphingosine-1-phosphate (S1P) analogue approved for the treatment of relapsing-remitting multiple sclerosis (RRMS). The identification of biomarkers of clinical responses to fingolimod is a major necessity in MS to identify optimal responders and avoid the risk of disease progression in non-responders. With this aim, we used RNA sequencing to study the transcriptomic changes induced by fingolimod in peripheral blood mononuclear cells of MS-treated patients and their association with clinical response. Samples were obtained from 10 RRMS patients (five responder

Стилі APA, Harvard, Vancouver, ISO та ін.

9

M Arif, Rana, Fahad Aman Khan, Imran Khan, Muzammil Aslam Kataria, Jawed Iqbal, and Mukhtar Ahmed. "Vitamin D Deficiency in HCV Antiviral Treatment Responders versus Non-Responders." Journal of Islamabad Medical & Dental College 8, no. 1 (2019): 45–49. http://dx.doi.org/10.35787/jimdc.v8i1.316.

Повний текст джерела

Анотація:

Background: Hepatitis C virus (HCV) is a major cause of chronic liver disease (CLD). Pakistan has a high burden of infectious diseases, including HCV. Its prevalence varies according to geographic regions in the country from about 2·4% to 6·5%. The objective of the study was to compare the frequency of vitamin D deficiency in responders and non-responders of antiviral treatment for chronic hepatitis C.Material and Methods: This comparative cross-sectional study was conducted in Hepatitis Clinic, Jinnah hospital, Lahore from 20th May to 20th November 2013. After ethical approval, participants w

Стилі APA, Harvard, Vancouver, ISO та ін.

10

Van Hoef, M. "Interim results of a survey to evaluate use and interest in autologous and allogeneic bone marrow transplant as a treatment option among patients." Journal of Clinical Oncology 27, no. 15_suppl (2009): e17569-e17569. http://dx.doi.org/10.1200/jco.2009.27.15_suppl.e17569.

Повний текст джерела

Анотація:

e17569 Background: A survey was placed on websites inviting patients to provide an opinion about bone marrow transplant as treatment option for their disease. Herein an interim analysis of results is presented. Methods: A survey was developed requesting general information about the responder, the disease, and the experience with and interest in autologous and allogeneic donor transplants as treatment option for disease. The survey was placed on sites in the Netherlands and Belgium (cancer fora and website) and was initially announced in a few magazins. Results: Several cancer fora in the Neth

Стилі APA, Harvard, Vancouver, ISO та ін.

11

Overeem, Lucas Hendrik, Andreas Peikert, Maxi Dana Hofacker, et al. "Effect of antibody switch in non-responders to a CGRP receptor antibody treatment in migraine: A multi-center retrospective cohort study." Cephalalgia 42, no. 4-5 (2021): 291–301. http://dx.doi.org/10.1177/03331024211048765.

Повний текст джерела

Анотація:

Background Switching between antibody classes might be a treatment option in migraine patients who have not responded to one class of a CGRP-(receptor) monoclonal antibody (mAb), but there are no efficacy data so far. In this real-world analysis, we assessed the treatment response to a CGRP-mAb in patients that have previously failed the CGRP-receptor-mAb erenumab. Methods We analyzed retrospective headache diary data of 78 patients with migraine who switched between CGRP-mAbs classes at four German headache centers either due to lack of efficacy or intolerable side effects. Among these, we id

Стилі APA, Harvard, Vancouver, ISO та ін.

12

Jackson, Christina, John Choi, JiaJia Zhang, et al. "IMMU-18. IMMUNOGENOMIC RESPONDER PHENOTYPE FROM A PHASE I TRIAL OF ANTI-LAG3 OR ANTI-CD137 ALONE AND IN COMBINATION WITH ANTI-PD-1 IN PATIENTS WITH RECURRENT GBM." Neuro-Oncology 21, Supplement_6 (2019): vi122—vi123. http://dx.doi.org/10.1093/neuonc/noz175.511.

Повний текст джерела

Анотація:

Abstract BACKGROUND Immune checkpoint inhibitors (ICIs) are not uniformly effective in glioblastoma treatment. Immunogenomic determinants may identify patients who are most likely to benefit from these therapies. Therefore, we compared the immunogenomic phenotype of a responder to combination anti-LAG-3 and anti-PD-1 therapy to non-responders. METHODS We performed T cell receptor (TCR) sequencing and gene expression analysis on pre-treatment, post-chemoradiation, and post-immunotherapy tumor specimens of glioblastoma patients treated with anti-LAG3 in combination with anti-PD-1 after first rec

Стилі APA, Harvard, Vancouver, ISO та ін.

13

Schoolcraft, William B. "Evaluation and Treatment of the Poor Responder." Clinical Obstetrics and Gynecology 49, no. 1 (2006): 23–33. http://dx.doi.org/10.1097/01.grf.0000197265.94917.1e.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

14

Corvino, Fabio, Francesco Giurazza, Paolo Marra, et al. "Damage Control Interventional Radiology in Liver Trauma: A Comprehensive Review." Journal of Personalized Medicine 14, no. 4 (2024): 365. http://dx.doi.org/10.3390/jpm14040365.

Повний текст джерела

Анотація:

The liver is the second most common solid organ injured in blunt and penetrating abdominal trauma. Non-operative management (NOM) has become the standard of care for liver injuries in stable patients, where transarterial embolization (TAE) represents the main treatment, increasing success rates and avoiding invasive surgical procedures. In hemodynamically (HD) unstable patients, operative management (OM) is the standard of care. To date, there are no consensus guidelines about the endovascular treatment of patients with HD instability or in ones that responded to initial infusion therapy. A re

Стилі APA, Harvard, Vancouver, ISO та ін.

15

Heidari, Somaye-Sadat, Nooshin Dalili, Shiva Samavat, et al. "A Urinary Proteomics Approach to Predict Treatment Response in Acute Antibody-Mediated Rejection." OBM Transplantation 07, no. 03 (2023): 1–25. http://dx.doi.org/10.21926/obm.transplant.2303196.

Повний текст джерела

Анотація:

Acute antibody-mediated rejection (AMR) is a severe complication affecting kidney allografts' long-term survival. Timely detection and appropriate treatment of AMR are crucial for improving graft outcomes. This study aimed to discover non-invasive urinary biomarkers that can predict the response to therapy in patients with AMR. Materials and Methods: In this case-control study, urine samples from 21 biopsy-proven AMR patients underwent proteomics using label-free quantification. The patients were divided into two groups: responders and non-responders to treatment based on their graft function.

Стилі APA, Harvard, Vancouver, ISO та ін.

16

Stip, E., I. Lussier, E. Ngan, A. Mendrek, and P. Liddle. "Discriminant cognitive factors in responder and non-responder patients with schizophrenia." European Psychiatry 14, no. 8 (1999): 442–50. http://dx.doi.org/10.1016/s0924-9338(99)00223-0.

Повний текст джерела

Анотація:

SummaryTo identify which improvements in cognitive function are associated with symptom resolution in schizophrenic patients treated with atypical antipsychotics. Design: a prospective open trial with atypical neuroleptics (risperidone, clozapine, quetiapine). Setting: Inpatient and outpatient units, Institute of Psychiatry. Patients: Thirty-nine patients with schizophrenia according to DSM-IV criteria were included. Clinical and cognitive assessment were done at baseline (T0) and again after six months of treatment (T2). Twenty-five patients completed the trial. Interventions: New-generation

Стилі APA, Harvard, Vancouver, ISO та ін.

17

Karlström, Patric, Ulf Dahlström, Kurt Boman, and Urban Alehagen. "Responder to BNP-guided treatment in heart failure. The process of defining a responder." Scandinavian Cardiovascular Journal 49, no. 6 (2015): 316–24. http://dx.doi.org/10.3109/14017431.2015.1070961.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

18

Nygaard, Rachel, Emily Colonna, Rediat Tilahun, et al. "90 Individual and Injury Characteristics of Response to Thrombolytic Therapy Following Severe Frostbite Injury." Journal of Burn Care & Research 46, Supplement_1 (2025): S73. https://doi.org/10.1093/jbcr/iraf019.090.

Повний текст джерела

Анотація:

Abstract Introduction Approximately 30% of severe frostbite injuries result in amputation. Thrombolytic therapy (tPA) is used to reduce tissue loss following severe frostbite injury. This study evaluates factors impacting the tPA effectiveness using post-tPA perfusion imaging and amputation level as outcome measures. We hypothesize that stratifying tPA-treated patients into full, partial, and non-responders will allow for a more nuanced assessment of treatment efficacy. Methods We reviewed a prospectively maintained frostbite database (2013–2020) for patients with post-rewarming perfusion defi

Стилі APA, Harvard, Vancouver, ISO та ін.

19

Mazzaferro, EM, DS Greco, AS Turner та MJ Fettman. "Treatment of feline diabetes mellitus using an α-glucosidase inhibitor and a low-carbohydrate diet". Journal of Feline Medicine and Surgery 5, № 3 (2003): 183–89. http://dx.doi.org/10.1016/s1098-612x(03)00006-8.

Повний текст джерела

Анотація:

The purpose of this study was to determine the effect of an α-glucosidase inhibitor (acarbose), combined with a low-carbohydrate diet on the treatment of naturally occurring diabetes mellitus in cats. Eighteen client-owned cats with naturally occurring diabetes mellitus were entered into the study. Dual-energy X-ray absorptiometry (DEXA) was performed prior to and 4 months after feeding the diet to determine total body composition, including lean body mass (LBM) and percent body fat. Each cat was fed a commercially available low-carbohydrate canned feline diet and received 12.5 mg/cat acarbose

Стилі APA, Harvard, Vancouver, ISO та ін.

20

Gustafsson, Kristin, Anna Cronström, Ola Rolfson, Eva Ageberg, and Therese Jönsson. "Responders to first-line osteoarthritis treatment had reduced frequency of hip and knee joint replacements within 5 years: an observational register-based study of 44,311 patients." Acta Orthopaedica 95 (July 15, 2024): 373–79. http://dx.doi.org/10.2340/17453674.2024.41011.

Повний текст джерела

Анотація:

Background and purpose: First-line treatment (education, exercise) for patients with hip and knee osteoarthritis (OA) aims to reduce pain and improve function. We aimed to compare progression to joint replacement within 5 years between responders and non-responders to first-line treatment for hip and knee OA, respectively.Methods: This observational study included data for 30,524 knee OA and 13,787 hip OA patients from the Swedish Osteoarthritis Register, linked with the Swedish Arthroplasty Register, Statistics Sweden, and the Swedish Prescribed Drug Register. The primary prognostic factor wa

Стилі APA, Harvard, Vancouver, ISO та ін.

21

Huang, W. N., Y. M. Chen, W. T. Hung, K. T. Tang, Y. W. Liao, and Y. H. Chen. "AB0379 IS MYCOPHENOLATE SODIUM (MYFORTIC) SIMILARLY EFFECTIVE AS MYCOPHENOLATE MOFETIL (CELLCEPT) IN TREATMENT OF LUPUS NEPHRITIS? EXPERIENCE FROM NON-MEDICAL SWITCHING REAL WORLD DATA IN TAIWAN." Annals of the Rheumatic Diseases 79, Suppl 1 (2020): 1490.1–1490. http://dx.doi.org/10.1136/annrheumdis-2020-eular.2325.

Повний текст джерела

Анотація:

Background:Lupus nephritis is the most important predictive factor of morbidity and mortality in SLE. Though Mycophenolate mofetil is recommended for induction and maintenance treatment of class III, IV V lupus nephritis, it is not approved by US or Taiwan FDA (TFDA). In previous reports of kidney transplantation, no efficacy differences were observed between mycophenolate sodium (Myfortic) and mycophenolate mofetil (Cellcept). However, no clinical trial was conducted to compare these two widely-used mycophenolic acid derivatives in lupus nephritis. In December, 2016, TFDA approved Mycophenola

Стилі APA, Harvard, Vancouver, ISO та ін.

22

Acker, J., F. Scholz, A. Piehl, K. Richter, and G. Niklewski. "FC26-05 - Differences in depression symptoms between RTMS responders and rTMS non-responders in a sample of tinnitus affected people." European Psychiatry 26, S2 (2011): 1963. http://dx.doi.org/10.1016/s0924-9338(11)73666-5.

Повний текст джерела

Анотація:

IntroductionThe clinic of psychiatry and psychotherapy and the clinic of otolaryngology of the clinic of Nuremberg offer an interdisciplinary consultation for patients suffering from tinnitus aurium and comorbid major depression and/or insomnia.ObjectivesPrediction variables are needed regarding the treatment of subjective ear noises by low frequency rTMS.The aim of the present study was to examinea)if rTMS responders and non-responders differ in significant parameters prior to the rTMS treatmentb)and if improvement of tinnitus complaints is associated with mood change.MethodsFrom June 2008 to

Стилі APA, Harvard, Vancouver, ISO та ін.

23

Menke, Marcel N., Andreas Ebneter, Martin S. Zinkernagel, and Sebastian Wolf. "Differentiation between Good and Low-Responders to Intravitreal Ranibizumab for Macular Edema Secondary to Retinal Vein Occlusion." Journal of Ophthalmology 2016 (2016): 1–6. http://dx.doi.org/10.1155/2016/9875741.

Повний текст джерела

Анотація:

Background. Ranibizumab is approved for treatment of macular edema in eyes with retinal vein occlusion (RVO). Some eyes show low-response to treatment with regard to visual acuity gain (VA) and OCT central retinal thickness (CRT) reduction. The goal of this study was to quantify the percentage of low-responders. Methods. Treatment of naïve eyes with macular edema secondary to RVO was included and monthly VA and CRT were analyzed. Four weeks after the loading phase, and at the end of the study, eyes were grouped into low- and good responders based on predefined criteria. The responder and low-r

Стилі APA, Harvard, Vancouver, ISO та ін.

24

Schreiber, S. W., D. B. Clemow, G. Yu, et al. "P1122 Identification of responder subpopulations in moderately-to-severely active Crohn’s disease patients treated with mirikizumab: Results from the VIVID-1 study." Journal of Crohn's and Colitis 19, Supplement_1 (2025): i2061—i2062. https://doi.org/10.1093/ecco-jcc/jjae190.1296.

Повний текст джерела

Анотація:

Abstract Background Mirikizumab (MIRI), an anti-IL-23p19 antibody, demonstrated robust efficacy in improving clinical and endoscopic endpoints with an acceptable safety profile in IBD1. Bowel urgency is common and impactful among patients with Crohn’s disease (CD).2 CD patients show a remarkable heterogeneity in their individual response levels to targeted therapies,3 including MIRI. We explored the existence of subgroups among MIRI-treated, moderate-to-severely active CD patients1 by investigating symptom trajectories and their relationship to treatment outcome. Methods A Growth Mixture Model

Стилі APA, Harvard, Vancouver, ISO та ін.

25

Seenivasan, S., M. Adamson, and A. Phillips. "Deep learning approach to evaluate sex differences in response to neuromodulation in Major Depressive Disorder." European Psychiatry 65, S1 (2022): S182. http://dx.doi.org/10.1192/j.eurpsy.2022.480.

Повний текст джерела

Анотація:

Introduction Identifying the factors that mediate treatment response to rTMS in MDD patients can guide clinicians to administer more appropriate, reliable, and personalized interventions. Objectives The present study aimed to investigate sex differences in response to repetitive transcranial magnetic stimulation (rTMS) in Major Depressive Disorder (MDD) patients. Methods In this paper, we developed a novel pipeline based on convolutional LSTM-based deep learning (DL) to classify 25 female and 25 male subjects based on their rTMS treatment response. Results Five different classification models

Стилі APA, Harvard, Vancouver, ISO та ін.

26

Kwon, Hyunwook, Young Hoon Kim, Youngmin Ko, et al. "Pure T-cell mediated rejection following kidney transplant according to response to treatment." PLOS ONE 16, no. 9 (2021): e0256898. http://dx.doi.org/10.1371/journal.pone.0256898.

Повний текст джерела

Анотація:

The focus of studies on kidney transplantation (KT) has largely shifted from T-cell mediated rejection (TCMR) to antibody-mediated rejection (ABMR). However, there are still cases of pure acute TCMR in histological reports, even after a long time following transplant. We thus evaluated the impact of pure TCMR on graft survival (GS) according to treatment response. We also performed molecular diagnosis using a molecular microscope diagnostic system on a separate group of 23 patients. A total of 63 patients were divided into non-responders (N = 22) and responders (N = 44). Non-response to reject

Стилі APA, Harvard, Vancouver, ISO та ін.

27

Sylwanowicz, Lauren, Merritt Schreiber, Craig Anderson, Carlos Primero D. Gundran, Emelie Santamaria, and Jaifred Christian F. Lopez. "Rapid Triage of Mental Health Risk in Emergency Medical Workers: Findings From Typhoon Haiyan." Disaster Medicine and Public Health Preparedness 12, no. 1 (2017): 19–22. http://dx.doi.org/10.1017/dmp.2017.37.

Повний текст джерела

Анотація:

AbstractObjectiveTo determine the ability of a novel responder mental health self-triage system to predict post-traumatic stress disorder (PTSD) in emergency medical responders after a disaster.MethodsParticipants in this study responded to Typhoon Haiyan, which struck the Philippines in November 2013. They completed the Psychological Simple Triage and Rapid Treatment (PsySTART) responder triage tool, the PTSD Checklist (PCL-5) and the Patient Health Questionnaire-8 (PHQ-8) shortly after responding to this disaster. The relationships between these 3 tools were compared to determine the associa

Стилі APA, Harvard, Vancouver, ISO та ін.

28

Esposito, Daniela, Fabiana Napolitano, Daniela Claudia Maresca, et al. "Early assessment of IL8 and PD1+ Treg predicts response and guides treatment monitoring in cemiplimab-treated cutaneous squamous cell carcinoma." Journal for ImmunoTherapy of Cancer 13, no. 1 (2025): e010421. https://doi.org/10.1136/jitc-2024-010421.

Повний текст джерела

Анотація:

PurposeAnti-programmed cell death 1 (PD1) is the first-choice treatment in patients with advanced cutaneous squamous cell carcinoma (cSCC), when curative options are unavailable. However, reliable biomarkers for patient selection are still lacking.Experimental designIn this translational study, clinical annotations, tissue and liquid biopsies were acquired to investigate the association between sustained objective responses and transcriptional profiles, immune cell dynamics in tumor tissue and peripheral blood samples, as well as circulating cytokine levels.ResultsFirst, we investigated the ba

Стилі APA, Harvard, Vancouver, ISO та ін.

29

Cappelleri, Joseph C., and Richard Chambers. "Addressing Bias in Responder Analysis of Patient-Reported Outcomes." Therapeutic Innovation & Regulatory Science 55, no. 5 (2021): 989–1000. http://dx.doi.org/10.1007/s43441-021-00298-5.

Повний текст джерела

Анотація:

Abstract Introduction Quantitative patient-reported outcome (PRO) measures ideally are analyzed on their original scales and responder analyses are used to aid the interpretation of those primary analyses. As stated in the FDA PRO Guidance for Medical Product Development (2009), one way to lend meaning and interpretation to such a PRO measure is to dichotomize between values where within-patient changes are considered clinically important and those that are not. But even a PRO scale with a cutoff score that discriminates well between responder and non-responders is fraught with some misclassif

Стилі APA, Harvard, Vancouver, ISO та ін.

30

Lee, Sang Yeob, Sun-Hee Park, Sung Won Lee, et al. "Synoviocyte apoptosis may differentiate responder and non-responder patients to methotrexate treatment in rheumatoid arthritis." Archives of Pharmacal Research 37, no. 10 (2014): 1286–94. http://dx.doi.org/10.1007/s12272-014-0365-x.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

31

Gao, Keming, Nicholas M. Kaye, Marzieh Ayati, et al. "Divergent Directionality of Immune Cell-Specific Protein Expression between Bipolar Lithium Responders and Non-Responders Revealed by Enhanced Flow Cytometry." Medicina 59, no. 1 (2023): 120. http://dx.doi.org/10.3390/medicina59010120.

Повний текст джерела

Анотація:

Background and Objectives: There is no biomarker to predict lithium response. This study used CellPrint™ enhanced flow cytometry to study 28 proteins representing a spectrum of cellular pathways in monocytes and CD4+ lymphocytes before and after lithium treatment in patients with bipolar disorder (BD). Materials and Methods: Symptomatic patients with BD type I or II received lithium (serum level ≥ 0.6 mEq/L) for 16 weeks. Patients were assessed with standard rating scales and divided into two groups, responders (≥50% improvement from baseline) and non-responders. Twenty-eight intracellular pro

Стилі APA, Harvard, Vancouver, ISO та ін.

32

Teirlinck, Carolien H., Arianne P. Verhagen, Elja A. E. Reijneveld, et al. "Responders to Exercise Therapy in Patients with Osteoarthritis of the Hip: A Systematic Review and Meta-Analysis." International Journal of Environmental Research and Public Health 17, no. 20 (2020): 7380. http://dx.doi.org/10.3390/ijerph17207380.

Повний текст джерела

Анотація:

The Outcome Measures in Rheumatology workgroup (OMERACT), together with the Osteoarthritis Research Society International (OARSI) developed the OMERACT-OARSI responder criteria. These criteria are used to determine if a patient with osteoarthritis (OA) ‘responds’ to therapy, meaning experiences a clinically relevant effect of therapy. Recently, more clinical OA trials report on this outcome and most OA trials have data to calculate the number of responders according to these criteria. A systematic review and meta-analysis were performed on the response to exercise therapy, compared to no or mi

Стилі APA, Harvard, Vancouver, ISO та ін.

33

Zaki, Seham Mahrous, Hanan Samir Ahmed, Monkez Motieh Yousif, and Eman Mohamed Awad. "Interleukin 28B Polymorphism as a Predictor of Sustained Virological Response to Sofosbuvir-Based Therapy for Hepatitis C Virus Patients." Tropical Medicine and Infectious Disease 7, no. 9 (2022): 230. http://dx.doi.org/10.3390/tropicalmed7090230.

Повний текст джерела

Анотація:

In various genome-wide correlation studies, interleukin (IL)28B gene polymorphism has been strongly correlated with both the therapeutic and spontaneous mediated clearance of hepatitis C virus (HCV). Therefore, this study aimed to evaluate the genotype and allele frequency distributions of IL28B (rs12979860) in patients with chronic hepatitis C and assess the IL28B polymorphisms as predictors of sustained virological response to SOF-based therapy for HCV in Egyptian patients. This retrospective case-control study was conducted on 54 chronic HCV patients who completed treatment with SOF/DCV ± R

Стилі APA, Harvard, Vancouver, ISO та ін.

34

Padula, Maria Carmela, Angela Anna Padula, Salvatore D’Angelo та ін. "TNFα rs1800629 Polymorphism and Response to Anti-TNFα Treatment in Behçet Syndrome: Data from an Italian Cohort Study". Journal of Personalized Medicine 13, № 9 (2023): 1347. http://dx.doi.org/10.3390/jpm13091347.

Повний текст джерела

Анотація:

Tumor Necrosis Factor-alpha (TNFα) rs1800629 (-308G>A) is a single nucleotide polymorphism (SNP) related to variable responses to anti-TNFα therapy. This therapy is efficient in severe and refractory manifestation of Behçet syndrome (BS), an auto-inflammatory systemic vasculitis. We investigated (1) the association between rs1800629 genotypes and responses to therapy and (2) the correlation between SNP and clinical patterns in a cohort of 74 BS Italian patients receiving anti-TNFα therapy with a follow-up of at least 12 months. The rs1800629 was genotyped through amplification, direct seque

Стилі APA, Harvard, Vancouver, ISO та ін.

35

Städtler, Gerald, Kaweh Shakery, Jan Endrikat, Richard Nkulikiyinka, and Christoph Gerlinger. "An empirically generated responder definition for rosacea treatment." Clinical, Cosmetic and Investigational Dermatology Volume 10 (September 2017): 347–52. http://dx.doi.org/10.2147/ccid.s139352.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

36

Ruf, Sabine, Margareta Bendeus, Hans Pancherz, and Urban Hägg. "Dentoskeletal Effects and “Effective” Temporomandibular Joint, Maxilla and Chin Changes in Good and Bad Responders to van Beek Activator Treatment." Angle Orthodontist 77, no. 1 (2007): 64–72. http://dx.doi.org/10.2319/120605-425r.1.

Повний текст джерела

Анотація:

Abstract Objective: To assess possible differences in dentoskeletal effects and “effective” temporomandibular joint, maxilla, and chin changes between good and bad responders to van Beek activator treatment. Materials and Methods: The subject material consisted of 20 consecutive normodivergent male Class II division 1 patients treated with a van Beek activator. Because of insufficient cooperation, four patients were excluded. Lateral head films were taken 6 months before treatment, at start of treatment, and after 12 months of treatment. The patients were placed into a good responder group (su

Стилі APA, Harvard, Vancouver, ISO та ін.

37

Newton, Hannah S., Vaibhavkumar S. Gawali, Ameet A. Chimote, et al. "PD1 blockade enhances K+ channel activity, Ca2+ signaling, and migratory ability in cytotoxic T lymphocytes of patients with head and neck cancer." Journal for ImmunoTherapy of Cancer 8, no. 2 (2020): e000844. http://dx.doi.org/10.1136/jitc-2020-000844.

Повний текст джерела

Анотація:

BackgroundImmunotherapy has emerged as a promising treatment modality for head and neck squamous cell carcinoma (HNSCC). Pembrolizumab, an anti-programmed death 1 antibody, is an immunotherapy agent currently approved for metastatic HNSCC and curative intent clinical trials. Although clinical responses to pembrolizumab are promising, many patients fail to respond. However, it is well known that T cell cytotoxicity and chemotaxis are critically important in the elimination of HNSCC tumors. These functions depend on ion channel activity and downstream Ca2+ fluxing abilities, which are defective

Стилі APA, Harvard, Vancouver, ISO та ін.

38

Chen, H. H., W. C. Chao, J. R. Wang, and T. M. Ko. "AB0108 USING RNA SEQUENCING TO IDENTIFY GENE EXPRESSION SIGNATURES ASSOCIATED WITH RESPONSE TO ABATACEPT IN PATIENTS WITH RHEUMATOID ARTHRITIS." Annals of the Rheumatic Diseases 80, Suppl 1 (2021): 1082–83. http://dx.doi.org/10.1136/annrheumdis-2021-eular.896.

Повний текст джерела

Анотація:

Background:Rheumatoid arthritis (RA) is a common chronic autoimmune disease. Abatacept (CTLA4-immunoglobulin) is one of the biological disease-modifying antirheumatic drug (bDMARD) for RA patients with indequate response to methotrexate. Recently, Yokoyama-Kokuryo et al. compared gene expression levels between abatacept responders and non-responders in RA patients using a microarray and found that type I IFN score and expression levels of nine genes may be used as a biomarker to predict response to abatacept. However, little study used RNA sequencing (RNA-seq) to identify whole blood gene expr

Стилі APA, Harvard, Vancouver, ISO та ін.

39

Felli, Chiara, Werner Güth, Esther Mata-Pérez, and Giovanni Ponti. "Ultimatum Concession Bargaining." Journal of Conflict Resolution 62, no. 5 (2016): 1012–43. http://dx.doi.org/10.1177/0022002716676312.

Повний текст джерела

Анотація:

We collect experimental evidence on a modified version of the standard ultimatum game in which the responder states an acceptance threshold below which the offer is rejected and both players, proposer and responder, are allowed several attempts to reach an agreement by conceding. Proposers concede by increasing offers and responders concede by decreasing acceptance thresholds. Treatments differ in whether a further attempt requires that at least one party should have conceded. A further condition varies the number of possible negotiating attempts, namely, 3 versus 5. Behavior in the lab diverg

Стилі APA, Harvard, Vancouver, ISO та ін.

40

Santillán, María E., Néstor O. Galizio, María E. Amrein, et al. "Cardiac Resynchronization Therapy. Long-Term Evolution of Responder and Non-Responder Patients." Revista Argentina de Cardiologia 92, no. 3 (2024): 211–16. http://dx.doi.org/10.7775/rac.v92.i3.20771.

Повний текст джерела

Анотація:

Background: Cardiac resynchronization therapy (CRT) is an effective treatment in patients with heart failure (HF), low left ventricular ejection fraction (LVEF) and wide QRS. However, there are a percentage of these patients who are non-responders, implying worse clinical outcomes. Objectives: The aim of this study was to assess the differences in echocardiographic parameters of reverse remodeling and event rates [hospitalization for heart failure (HHF), all-cause mortality (ACM), heart transplantation (HTX) and appropriate therapies (AT)] between responder vs. non-responder patients to CRT. M

Стилі APA, Harvard, Vancouver, ISO та ін.

41

Hara, Chikako, Taku Wakabayashi, Hiroshi Toyama, et al. "Characteristics of patients with neovascular age-related macular degeneration who are non-responders to intravitreal aflibercept." British Journal of Ophthalmology 103, no. 5 (2018): 623–29. http://dx.doi.org/10.1136/bjophthalmol-2018-312275.

Повний текст джерела

Анотація:

PurposeTo investigate the frequency and patient characteristics that influence anatomic response of intravitreal aflibercept in treatment-naïve neovascular age-related macular degeneration (AMD).DesignRetrospective, interventional, consecutive case series.MethodsThree hundred and sixty-five eyes of 365 patients with AMD who underwent 3 monthly intravitreal aflibercept treatments with follow-up for at least 12 months were investigated. Treatment response was evaluated as follows. Responders were defined as those with complete resolution of exudation, including intraretinal oedema, subretinal fl

Стилі APA, Harvard, Vancouver, ISO та ін.

42

Cheng, Michael Kin-Fun, Justine Joseph, and Donna Ferguson. "A Cognitive Behavioral Model of First Responder Posttraumatic Stress Disorder." Journal of Cognitive Psychotherapy 32, no. 3 (2018): 184–91. http://dx.doi.org/10.1891/0889-8391.32.3.184.

Повний текст джерела

Анотація:

First responders face significant risks with respect to their mental health including exposure to traumatic events and subsequent development of posttraumatic stress disorder (PTSD). There are many established psychological treatment guidelines for PTSD, but there are reasons to believe that first responders differ significantly from the general population and would benefit from a targeted approach to treatment planning. The authors present a cognitive behavioral model of first responder PTSD, which integrates important factors related to this population as well as an illustrative case study.

Стилі APA, Harvard, Vancouver, ISO та ін.

43

Zimmerman, M. "50% Improvement: Should Treatment Response Go Beyond Symptom Improvement When Evaluating the Treatment of Depression?" European Psychiatry 66, S1 (2023): S415. http://dx.doi.org/10.1192/j.eurpsy.2023.895.

Повний текст джерела

Анотація:

IntroductionThe emphasis on symptom resolution in depression treatment research is at variance with the recommendations of official treatment guidelines and the results of surveys of depressed patients’ views of the most important treatment goals.ObjectivesIn the present study, we examined the interrelationship between response rates on various outcome domains and whether response on each domain was associated with patients’ global rating of improvement (PGI) reported upon treatment completion. We also examined whether the PGI was associated with the number of domains on which the patients had

Стилі APA, Harvard, Vancouver, ISO та ін.

44

Tamburini, A., A. Castiglioni, M. C. Salandini, et al. "303 Cytotoxic treatment for rectal cancer reveals different innate immunity in responder and non-responder patients." European Journal of Cancer Supplements 8, no. 5 (2010): 78. http://dx.doi.org/10.1016/s1359-6349(10)71107-1.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

45

Lee, S. Y., J. H. Bae, S. W. Lee, and W. T. Chung. "THU0253 Synoviocyte Apoptosis May Differentiate Responder and Non-Responder Patients to Methotrexate Treatment in Rheumatoid Arthritis." Annals of the Rheumatic Diseases 72, Suppl 3 (2013): A251.1—A251. http://dx.doi.org/10.1136/annrheumdis-2013-eular.781.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

46

Din, Nizamud, Jamalud Din, Abid Shah, and Waheed Iqbal. "SOFOSBUVIR AND RIBAVIRIN." Professional Medical Journal 25, no. 12 (2018): 1876–81. http://dx.doi.org/10.29309/tpmj/18.4587.

Повний текст джерела

Анотація:

Objectives: This study was conducted to evaluate the 16-weeks versus 24-weeks efficacy of sofosbuvir and ribavirin in HCV genotype-3a infection. Study Design: Open labeled, single center, longitudinal study. Setting: Khyber Medical College and Khyber Teaching Hospital, Peshawar. Period: The total duration of study was 6-months, starting from January 2017 to July 2017. Methods: Eighty patients with HCV genotype-3a infection wereenrolled. Patients were assigned into 4-groups (20 patients in each group), including group-A as treatment naïve non-cirrhotic, group-B as treatment naïve with liver cir

Стилі APA, Harvard, Vancouver, ISO та ін.

47

Lind, Hanne, Alexander Strait, Spencer Hall, et al. "Abstract 6646: Investigating the combination of radiation and subsequent immune checkpoint inhibitor treatment in head and neck squamous cell carcinoma models." Cancer Research 84, no. 6_Supplement (2024): 6646. http://dx.doi.org/10.1158/1538-7445.am2024-6646.

Повний текст джерела

Анотація:

Abstract Purpose: Head and neck squamous cell carcinoma (HNSCC) is often marked by an immunosuppressive tumor microenvironment, which contributes to the dismal 10-20% response rate to immune checkpoint inhibitor (ICI) therapy in HNSCC patients. Radiotherapy (RT) is a currently standard of care and frontline therapy for HNSCC, yet resistance is common. We sought to examine the combination therapy of RT followed by ICI therapy to test if RT induces an in situ vaccination which enhances the efficacy of subsequent ICI. Methods: We utilized SCC cell lines derived from K15.KrasG12D/Smad4−/− SCCs, wh

Стилі APA, Harvard, Vancouver, ISO та ін.

48

Garcia, Gustavo, Nikhil Chakravarty, Sophia Paiola, et al. "Differential Susceptibility of Ex Vivo Primary Glioblastoma Tumors to Oncolytic Effect of Modified Zika Virus." Cells 12, no. 19 (2023): 2384. http://dx.doi.org/10.3390/cells12192384.

Повний текст джерела

Анотація:

Glioblastoma (GBM), the most common primary malignant brain tumor, is a highly lethal form of cancer with a very limited set of treatment options. High heterogeneity in the tumor cell population and the invasive nature of these cells decrease the likely efficacy of traditional cancer treatments, thus requiring research into novel treatment options. The use of oncolytic viruses as potential therapeutics has been researched for some time. Zika virus (ZIKV) has demonstrated oncotropism and oncolytic effects on GBM stem cells (GSCs). To address the need for safe and effective GBM treatments, we de

Стилі APA, Harvard, Vancouver, ISO та ін.

49

Hinkley, Bruce, and Matt E. Jaremko. "Addressing the Psychosocial Needs of Orthopedic Pain Patients." Perceptual and Motor Skills 74, no. 3_suppl (1992): 1137–38. http://dx.doi.org/10.2466/pms.1992.74.3c.1137.

Повний текст джерела

Анотація:

Analysis of comprehensive examinations of 258 patients with orthopedic pain yielded 5 types of pain responders. Research is under way to analyze the response to pain and effectiveness of response treatment for each type of pain responder.

Стилі APA, Harvard, Vancouver, ISO та ін.

50

Mockute, Ruta, Alvita Vilkeviciute, Vilma Jurate Balciuniene, Reda Zemaitiene, and Rasa Liutkeviciene. "ABCA1 rs1883025 and CYP4F2 rs2108622 Gene Polymorphism Association with Age-Related Macular Degeneration and Anti-VEGF Treatment." Medicina 57, no. 9 (2021): 974. http://dx.doi.org/10.3390/medicina57090974.

Повний текст джерела

Анотація:

Background and Objectives: The age-related macular degeneration (AMD) pathophysiology is multifactorial, as it consists of interactions between aging, genetic, and environmental factors. We aimed to determine a relationship between AMD and the genes controlling lipid metabolism, and to assess its association with treatment results. The purpose was to find the ABCA1 rs1883025 and CYP4F2 rs2108622 gene polymorphisms in patients with exudative AMD (eAMD) treated with anti-VEGF. Materials and Methods: The study enroled 104 patients with eAMD and 201 healthy persons in a control group. The genotypi

Стилі APA, Harvard, Vancouver, ISO та ін.

Ми пропонуємо знижки на всі преміум-плани для авторів, чиї праці увійшли до тематичних добірок літератури. Зв'яжіться з нами, щоб отримати унікальний промокод!